As of late, it has definitely been a great time to be an investor in Catabasis Pharmaceuticals, Inc. CATB. The stock has moved higher by 29.8% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider CATB’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as CATB has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catabasis Pharmaceuticals, Inc. (CATB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research